Table 1 Selected first-line phase 3 trials in EGFR mutant NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
FLAURA | NCT02296125 | Osimertinib vs gefitinib or erlotinib | 80 vs 76 | 18.9 vs 10.2 (HR 0.46) | 38.6 vs 31.8 (HR 0.80) |
ARCHER | NCT01774721 | Dacomitinib vs gefitinib | 75 vs 72 | 14.7 vs 9.2 (HR 0.59) | 34.1 vs 26.8 (HR 0.76) |
LUX-Lung 7 | NCT01466660 | Afatinib vs gefitinib | 70 vs 56 | 11 vs 10.9 (HR 0.73) | 27.9 vs 24.05 (HR 0.86) |
LASER301 | NCT04248829 | Lazertinib vs gefitinib | 76 vs 76 | 20.6 vs 9.7 (HR 0.45) | NR vs NR (HR 0.74) |
FURLONG | NCT03787992 | Furmonertinib vs gefitinib | 89 vs 84 | 20.8 vs 11.1 (HR 0.44) | NR vs NR (HR 0.94) |
AENEAS | NCT03849768 | Aumolertinib vs gefitinib | 74 vs 72 | 19.3 vs 9.9 (HR 0.46) | NR vs NR |
Lu et al | NCT04206072 | Befotertinib vs icotinib | 76 vs 78 | 22.1 vs 13.8 (HR 0.49) | NR vs NR |